Matthew A. Sherman

Also affiliated with National Institute of Allergy and Infectious Diseases

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial”.

Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial

JCI Insight(2025)10.1172/jci.insight.191266

N/A

0.104DataRank · unranked

1 citations

Catriona A. Wagner, Ashley Pinckney, Jeffrey A. Cohen, Zachary S. Wallace, Arezou Khosroshahi +36 more

Autoantibodies Recognizing Specificity Protein 4 Co‐occur With Anti–Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis

Arthritis & Rheumatology(2023)10.1002/art.42512

N/A

0DataRank · unranked

14 citations

Katherine Pak, Iago Pinal‐Fernandez, Willy A. Flegel, Ira N. Targoff, Frederick W. Miller +4 more

Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study

Pediatric Rheumatology(2023)10.1186/s12969-023-00858-z

N/A

0DataRank · unranked

11 citations

Christopher Redmond, Emily C. Gotschlich, Sangeeta Sule, Tova Ronis, Kathleen M. Vazzana +9 more

Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance

Pediatric Rheumatology(2023)10.1186/s12969-022-00785-5

N/A

0DataRank · unranked

12 citations

Hanna Kim, Katelyn M. Banschbach, Amanda Brown, Harry L. Gewanter, Bianca Lang +9 more

Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti‐Transcriptional Intermediary Factor 1γ Juvenile‐Onset Dermatomyositis

Arthritis & Rheumatology(2023)10.1002/art.42768

N/A

0DataRank · unranked

6 citations

Qingyuan Yang, Laura Gutierrez‐Alamillo, Katherine Pak, Willy A. Flegel, Andrew L. Mammen +4 more

Clinical Outcomes and Safety of Anakinra in the Treatment of Multisystem Inflammatory Syndrome in Children: a Single Center Prospective Observational Study

Research Square(2023)10.21203/rs.3.rs-2773340/v1

N/A

0DataRank · unranked

0 citations

Christopher Redmond, Emily C. Gotschlich, Sangeeta Sule, Tova Ronis, Kathleen M. Vazzana +9 more

Myositis‐Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality

Arthritis & Rheumatology(2024)10.1002/art.42813

N/A

0DataRank · unranked

5 citations

Payam Noroozi Farhadi, Katherine Pak, Edward P. Trieu, Kakali Sarkar, Ira N. Targoff +5 more

Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features

Lara D. Veeken(2022)10.1093/rheumatology/keac428

N/A

0DataRank · unranked

4 citations

Rose Graf, Sara Sabbagh, Angeles S. Galindo‐Feria, Iago Pinal‐Fernandez, Katherine Pak +70 more

Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers

Lara D. Veeken(2025)10.1093/rheumatology/keaf086

N/A

0DataRank · unranked

1 citations

Rebecca Nicolai, E. Datyner, Silvia Rosina, Angela Hamilton, Kaveh Ardalan +15 more